Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00016718 |
Recruitment Status
:
Completed
First Posted
: August 31, 2001
Results First Posted
: October 17, 2017
Last Update Posted
: October 17, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Infections | Drug: Didanosine (ddI) Drug: Efavirenz (EFV) Drug: Emtricitabine (FTC) | Phase 1 Phase 2 |
Anti-HIV treatment options are limited for pediatric patients because combination therapies recommended for adults may not be appropriate for children or adolescents. Few PIs are available in formulations appropriate for pediatric patients, and complex dosing schedules and food requirements may be detrimental to treatment adherence. A once-daily regimen of the NRTIs ddI and FTC and the nonnucleoside reverse transcriptase inhibitor (NNRTI) EFV has been shown safe and well tolerated in adults.
This Phase I/II open label study evaluated the long-term safety and efficacy of a ddI, FTC, and EFV regimen in pediatric patients. All study patients were either absolutely naive to antiretroviral therapy or had received less than or equal to 56 days perinatal prophylaxis or less than 7 days of cumulative antiretroviral therapy prior to study entry, and had a plasma screening plasma HIV-1 RNA levels >= 5000 copies/mL. This study was written to characterize the disposition of FTC, determine the PK data for ddI-EC QD, comparing the bio-availability of the enteric coated formulation with ddI pediatric powder for oral solution, and to provide insight into the age related pharmacokinetics differences observed in this and other studies.
HIV infected pediatric patients were stratified into three age Groups: Group 1: 90 days to <3 years of age; Group 2: 3 years to 12 years of age (inclusive); and Group 3: 13 to 21 years of age (inclusive). The initial study doses for the triple drug regimen was FTC, 6 mk/kg up to a maximum of 200 mg once daily, for EFV, the dose for age Group 1 was determined in PACTG 382 and dose adjusted for body size, and the doses for age Groups 2 and 3 were defined in the dosing table of the protocol of up to a maximum of 600 mg once daily as a capsule or 720 mg as an oral solution; for ddI, 240 mg/m2 up to a maximum of 400 mg once daily. Comparison of age groups was not required as per the protocol.
Patients were followed for a maximum of 192 weeks; all patients were to receive ddI, EFV, and FTC together once daily. Study visits occurred at study entry, Weeks 2,and 4, and every 4 weeks thereafter. Blood collection, medical history assessment, and a physical exam occurred at all visits; urine collection occurred at selected visits. Intensive pharmacokinetic (PK) studies was done at Weeks 2 and 12 to determine if dose adjustments were required for any of the drugs. If virologic failure was determined, PK studies was repeated 4 weeks after adjustments in therapy. Parents or guardians were asked to complete treatment adherence questionnaires at some visits. Some patients were also asked to participate in an additional PK study after Week 16 or week 96.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 43 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Masking Description: | open-label |
Primary Purpose: | Treatment |
Official Title: | An Open-Label Study to Evaluate the Safety, Tolerance, Antiviral Activity, and Pharmacokinetics of Emtricitabine in Combination With Efavirenz and Didanosine in a Once-Daily Regimen in HIV Infected, Antiretroviral Therapy Naive or Very Limited Antiretroviral Exposed Pediatric Subjects |
Study Start Date : | August 2001 |
Actual Primary Completion Date : | January 2009 |
Actual Study Completion Date : | January 2009 |

Arm | Intervention/treatment |
---|---|
Experimental: Age Group 1: 90 days to < 3 years of age (FTC, EFV, ddI)
Emtricitabine (FTC), Efavirenz (EFV) and Didanosine (ddI) together once daily
|
Drug: Didanosine (ddI)
Antiretroviral Didanosine (ddI) : 240 mg/m^2 up to a maximum of 400 mg once daily
Other Name: Videx, Videx EC
Drug: Efavirenz (EFV)
Antiretroviral For Age Group 1 Efavirenz (EFV): dose adjusted for body size and for Age Groups 2 and 3 Efavirenz (EFV): up to a maximum of 600 mg once daily as a capsule ot 720 mg as an oral solution
Other Name: Sustiva
Drug: Emtricitabine (FTC)
Antiretroviral Emtricitabine (FTC): 6 mg/Kg up to a maximum of 200 mg once daily
Other Name: Emtriva
|
Experimental: Age Group 2: 3 to 12 years of age (FTC, EFV, ddI)
Emtricitabine (FTC), Efavirenz (EFV) and Didanosine (ddI) together once daily
|
Drug: Didanosine (ddI)
Antiretroviral Didanosine (ddI) : 240 mg/m^2 up to a maximum of 400 mg once daily
Other Name: Videx, Videx EC
Drug: Efavirenz (EFV)
Antiretroviral For Age Group 1 Efavirenz (EFV): dose adjusted for body size and for Age Groups 2 and 3 Efavirenz (EFV): up to a maximum of 600 mg once daily as a capsule ot 720 mg as an oral solution
Other Name: Sustiva
Drug: Emtricitabine (FTC)
Antiretroviral Emtricitabine (FTC): 6 mg/Kg up to a maximum of 200 mg once daily
Other Name: Emtriva
|
Experimental: Age Group 2: 13 to 21 years of age (FTC, EFV, ddI)
Emtricitabine (FTC), Efavirenz (EFV) and Didanosine (ddI) together once daily
|
Drug: Didanosine (ddI)
Antiretroviral Didanosine (ddI) : 240 mg/m^2 up to a maximum of 400 mg once daily
Other Name: Videx, Videx EC
Drug: Efavirenz (EFV)
Antiretroviral For Age Group 1 Efavirenz (EFV): dose adjusted for body size and for Age Groups 2 and 3 Efavirenz (EFV): up to a maximum of 600 mg once daily as a capsule ot 720 mg as an oral solution
Other Name: Sustiva
Drug: Emtricitabine (FTC)
Antiretroviral Emtricitabine (FTC): 6 mg/Kg up to a maximum of 200 mg once daily
Other Name: Emtriva
|
- Proportion of Participants Who Developed Grade 3 or 4 Adverse Events Attributed to the Study Treatment. [ Time Frame: At study entry, weeks 2 and 4, every 4 weeks up to week 96 and every 6 weeks thereafter for Group 1 participants and at study entry, weeks 2 and 4, every 4 weeks up to week 144 and every 12 weeks thereafter for Groups 2 and 3 ]
Adverse events were graded using the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 1.0, December 2004, Clarification August 2009, which is available on the RCC website at (http://rcc.tech-res.com/). Adverse Events of Grade 3 or 4 laboratory abnormalities or signs and symptoms that were judged by the study team to be possibly or probably related to the study treatment.
Comparisons between age groups were not required as per protocol.
- Proportion of Participants With Suppression of HIV Viral Load to Less Than 400 Copies/ml at Week 16 [ Time Frame: At week 16 ]Proportion was calculated as number of participants with HIV-1 RNA <= 400 copies/ml relative to the number of participants with HIV-1 RNA measured at that time point.
- Proportion of Participants With Suppression of HIV Viral Load to Less Than 50 Copies/ml at Week 16 [ Time Frame: At week 16 ]Proportion was calculated as number of participants with HIV-1 RNA <= 50 copies/ml relative to the number of participants with HIV-1 RNA measured at that time point.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 90 Days to 21 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- HIV infected
- Antiretroviral naive OR have received no more than 56 days of drugs to prevent mother-to-child transmission of HIV OR have received less than 7 total days of antiretroviral therapy
- Viral load of 5,000 copies/ml or more
- Any Center for Disease Control (CDC) classification and immune status
- Able to swallow study medications
- Parent or guardian willing to provide informed consent, if applicable
- Willing to use acceptable forms of contraception
- female subjects of childbearing potential with a negative serum beta human chronic gonadotropin
Exclusion Criteria:
- Allergic to study medications or their formulations
- Kidney disease
- Positive for hepatitis B or C
- Acute opportunistic infection (OI) or bacterial infection requiring treatment at study entry
- Taking drugs to treat tuberculosis
- Taking anti-HIV drugs other than those included in this study
- Hemoglobin >= grade 3 at screening
- Absolute Neutrophil counts >= grade 2 at screening
- Platelets >= Grade 2 at screening
- Bilirubin >= Grade 2 at screening
- SGOT (AST), SGPT(ALT) >= Grade 2 at screening
- Non-fasting triglycerides >= Grade 2 at screening. Confirmed by a 2nd determination >=100 mg/dl at fasting state
- Pancreatic amylase or total amylase+ lipase >= Grade 2 at screening
- Taking any investigational drugs
- Anti-cancer drugs within 1 year of study screening
- Serious medical event within 21 days of study screening
- Active or history of pancreatitis
- Require certain medications. Patients requiring short courses of steroids (less than 14 days) for asthma are not excluded.
- Active or history of significant peripheral neuropathy
- Difficulty with food or severe chronic diarrhea within 30 days before study entry
- Unable to eat at least 1 meal per day (or to feed at least 3 times per day, for infants) because of chronic nausea, vomiting, swallowing problems, or stomach upset
- Unable to swallow oral medications
- Pregnant or breastfeeding

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00016718
United States, California | |
UCSD Maternal, Child, and Adolescent HIV CRS | |
San Diego, California, United States | |
UCSF Pediatric AIDS CRS | |
San Francisco, California, United States, 941430105 | |
United States, Colorado | |
Univ. of Colorado Denver NICHD CRS | |
Aurora, Colorado, United States, 802181088 | |
United States, District of Columbia | |
Howard Univ. Washington DC NICHD CRS | |
Washington, D.C., District of Columbia, United States, 20060 | |
United States, Florida | |
Univ. of Florida Jacksonville NICHD CRS | |
Jacksonville, Florida, United States, 32209 | |
Univ. of Miami Ped. Perinatal HIV/AIDS CRS | |
Miami, Florida, United States, 33161 | |
United States, Illinois | |
Chicago Children's CRS | |
Chicago, Illinois, United States, 606143394 | |
Rush Univ. Cook County Hosp. Chicago NICHD CRS | |
Chicago, Illinois, United States | |
United States, Massachusetts | |
Children's Hosp. of Boston NICHD CRS | |
Boston, Massachusetts, United States, 021155724 | |
WNE Maternal Pediatric Adolescent AIDS CRS | |
Worcester, Massachusetts, United States, 016550001 | |
United States, New York | |
Nyu Ny Nichd Crs | |
New York, New York, United States, 10016 | |
Harlem Hosp. Ctr. NY NICHD CRS | |
New York, New York, United States | |
SUNY Upstate Med. Univ., Dept. of Peds. | |
Syracuse, New York, United States, 13210 | |
United States, North Carolina | |
DUMC Ped. CRS | |
Durham, North Carolina, United States, 277103499 | |
United States, Tennessee | |
St. Jude/UTHSC CRS | |
Memphis, Tennessee, United States, 381052794 | |
United States, Texas | |
Texas Children's Hosp. CRS | |
Houston, Texas, United States, 77030 | |
Puerto Rico | |
Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS | |
San Juan, Puerto Rico, 009365067 | |
San Juan City Hosp. PR NICHD CRS | |
San Juan, Puerto Rico, 009367344 |
Study Chair: | Ross E. McKinney, Jr., MD | Duke University | |
Study Chair: | Mobeen H. Rathore, MD | Pediatric Infectious Diseases/Immunology, University of Florida Health Science Center |
Additional Information:
Publications of Results:
Other Publications:
Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
ClinicalTrials.gov Identifier: | NCT00016718 History of Changes |
Other Study ID Numbers: |
P1021 10038 ( Registry Identifier: DAIDS ES ) ACTG P1021 PACTG P1021 IMPAACT P1021 |
First Posted: | August 31, 2001 Key Record Dates |
Results First Posted: | October 17, 2017 |
Last Update Posted: | October 17, 2017 |
Last Verified: | September 2017 |
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Didanosine Drug Therapy, Combination Drug Administration Schedule Reverse Transcriptase Inhibitors Anti-HIV Agents |
Pharmacokinetics Deoxycytidine Efavirenz Treatment Naive |
Additional relevant MeSH terms:
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Emtricitabine Efavirenz Didanosine Antiviral Agents Anti-Infective Agents |
Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Retroviral Agents Anti-HIV Agents Cytochrome P-450 CYP2C9 Inhibitors Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 CYP2C19 Inhibitors Cytochrome P-450 CYP2B6 Inducers Cytochrome P-450 Enzyme Inducers Cytochrome P-450 CYP3A Inducers Antimetabolites |